J. O’Sullivan
Oncology · New England Journal of Medicine · 2009–2018
A researcher in the Science corpus: 8 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 24 citations into it
- Electronic, Optical and Magnetic Materials — 10 citations into it
- Biomaterials — 9 citations into it
- Biomedical Engineering — 9 citations into it
- Molecular Biology — 9 citations into it
Whom J. O’Sullivan trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from J. O’Sullivan's perspective
Ordered by how strongly the researchers J. O’Sullivan trusts endorse each paper. Same corpus, a different order for every researcher.
- The use of gold nanoparticles to enhance radiotherapy in mice. (Physics in Medicine and Biology)
- Gold nanoparticles: a new X-ray contrast agent. (British Journal of Radiology)
- Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. (Nano letters (Print))
- Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery (Drug Delivery)
- Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. (Nano letters (Print))
- The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. (Advances in Enzyme Regulation)
- Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study (The Lancet Oncology)
- Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. (New England Journal of Medicine)
- Nanoshell-enabled photothermal cancer therapy: impending clinical impact. (Accounts of Chemical Research)
- Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. (Small)
Their papers
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial (2018) — 1,047 citations
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (2017) — 1,576 citations
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial (2016) — 1,183 citations
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial (2016) — 1,799 citations
- Alpha emitter radium-223 and survival in metastatic prostate cancer. (2013) — 3,066 citations
- Erratum: Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. (Scientific Reports) (2013) — 205 citations
- Gold nanoparticles as novel agents for cancer therapy. (2012) — 1,011 citations
- Radiation-induced bystander signalling in cancer therapy (2009) — 797 citations